Yngen Marianne, Norhammar Anna, Hjemdahl Paul, Wallén N Håkan
Karolinska University Hospital, Solna, SE-171 76 Stockholm, Sweden.
Diab Vasc Dis Res. 2006 May;3(1):52-6. doi: 10.3132/dvdr.2006.008.
The aim of this study was to investigate the impact of improved metabolic control on platelet reactivity in patients with type 2 diabetes undergoing percutaneous coronary intervention (PCI). Twenty-two patients were randomised to intensive insulin or conventional treatment for diabetes. Platelet P-selectin expression was analysed before and three months after PCI. Metabolic control, as measured by level of glycosylated haemoglobin (HbA1c) and platelet P-selectin expression, was similar in the two treatment groups after three months. However, six of the 12 patients in the intensive group had increased levels of HbA1c after three months and three patients of the 10 in the conventionally treated group showed improved metabolic control. A re-analysis was performed, based on metabolic control. It showed that patients with improved control at three months (HbA1c 6.1% +/- 0.7 at baseline; 5.7% +/- 0.5 at three months; p<0.01; n=9) had lower ADP-induced P-selectin expression (p<0.05) than patients with worsened glycaemic control (HbA1c 5.9% +/- 1.0 at baseline; 6.5% +/- 1.4 at three months; p<0.01; n=13). Levels of HbA1c and fasting glucose were correlated to P-selectin expression (R=0.34 and R=0.31; p<0.05). We conclude from this study that improved glycaemic control reduces platelet reactivity in type 2 diabetes patients following PCI.
本研究旨在调查改善代谢控制对接受经皮冠状动脉介入治疗(PCI)的2型糖尿病患者血小板反应性的影响。22例患者被随机分为强化胰岛素治疗组或糖尿病常规治疗组。在PCI术前及术后3个月分析血小板P-选择素的表达。3个月后,两组患者的代谢控制情况(通过糖化血红蛋白(HbA1c)水平和血小板P-选择素表达来衡量)相似。然而,强化治疗组12例患者中有6例在3个月后HbA1c水平升高,常规治疗组10例患者中有3例代谢控制得到改善。基于代谢控制情况进行了重新分析。结果显示,3个月时代谢控制改善的患者(基线时HbA1c为6.1%±0.7;3个月时为5.7%±0.5;p<0.01;n=9),其ADP诱导的P-选择素表达低于血糖控制恶化的患者(基线时HbA1c为5.9%±1.0;3个月时为6.5%±1.4;p<0.01;n=13)。HbA1c水平和空腹血糖与P-选择素表达相关(R=0.34和R=0.31;p<0.05)。我们从本研究得出结论,改善血糖控制可降低PCI术后2型糖尿病患者的血小板反应性。